Merck : New Data Released at Major Diabetes Meeting on Initial Combination Therapy with JANUVIA (sitagliptin), Merck's Diabetes Medicine, & Metformin

June 7, 2008 - New data presented at the American Diabetes Association (ADA) 68^th Annual Scientific Sessions showed initial combination therapy with JANUVIA™ (sitagliptin), a diabetes medicine from Merck & Co., Inc., and metformin substantially improved markers of beta cell function and significantly reduced blood sugar levels (as measured by A1Cⁱ) at one year and two years.

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin. JANUVIA is contraindicated for patients with history of a serious hypersensitivity reaction to sitagliptin, including anaphylaxis and angioedema... Merck's Press Release -